BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reported its unaudited...
Source: prnewswire.com